FDA Action Update: Designations (19th September 2024)
Glycomine received FTD for GLM101 Glycomine, Inc. has received FDA Fast Track Designation for GLM101, a mannose-1-phosphate replacement therapy aimed at treating phosphomannomutase 2-congenital disorder of glycosylation...